Phase II trial of BI-505 in myeloma terminated

The Swedish biotechnology company, BioInvent, has announced it has terminated a Phase I/ II trial of its lead drug BI-505 as a treatment in conjunction with high-dose therapy and stem cell transplantation (HDT-SCT) for newly diagnosed myeloma patients. This follows the verbal notice issued in November 2016 by the US Food and Drug Administration (FDA)…

Details